Inactive Instrument

Press Releases ESSA Pharma Inc Toronto S.E.

Equities

EPI

CA29668H1047

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 09	PR
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS	Mar. 07	PR
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS	Mar. 07	AQ
ESSA Pharma : Passive Foreign Investment Company Statement	Feb. 27	PU
ESSA Pharma: Fiscal Q1 Earnings Snapshot	Feb. 13	AQ
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023	Feb. 13	AQ
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Feb. 06	PR
ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium	Jan. 26	AQ
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 2024 ASCO Genitourinary Cancers Symposium	Jan. 25	PR
ESSA Pharma: Fiscal Q4 Earnings Snapshot	Dec. 12	AQ
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2023	Dec. 12	AQ
ESSA Pharma to Present at the Piper Sandler 35th Annual Healthcare Conference	Nov. 21	PR
ESSA Pharma to Present at the Jefferies London Healthcare Conference	Nov. 08	PR
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement	Nov. 06	PR
ESSA Pharma Enters into At-The-Market Equity Offering Sales Agreement	Nov. 06	AQ
ESSA Pharma : Enters into At-The-Market Equity Offering Sales Agreement - Form 8-K	Nov. 06	PU
ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	23-10-27	AQ
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	23-10-26	PR
ESSA Pharma Presents Updated Phase 1 Masofaniten (EPI-7386) Clinical Data at the 30th Annual Prostate Cancer Foundation Scientific Retreat	23-10-26	AQ
ESSA Pharma Presents Updated Phase 1 Masofaniten Clinical Data at the European Society of Medical Oncology 2023 Congress	23-10-23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases ESSA Pharma Inc Toronto S.E.

Equities

EPI

CA29668H1047

Press Releases

Filters